Photo-tunable interlayer drug delivery system for sustained heparin release in vascular grafts

A small-diameter vascular graft includes a heparin-loaded gelatin interlayer whose UV crosslinking is tuned by 3D-printed masks to control heparin release, reducing clotting and supporting healthy vessel lining.

Background

The field of small-diameter vascular grafts plays a critical role in coronary artery bypass surgery, where synthetic or bioengineered vessels replace blocked arteries to restore blood flow. Successful grafts must both prevent blood clots and integrate with the patient’s own tissue to avoid long-term complications. Despite advances in materials and surgical techniques, many grafts fail due to early thrombus formation and poor healing at the implant site. This has driven a need for technologies that can deliver anticoagulant drugs directly at the graft interface, offering sustained, localized protection without the risks associated with systemic treatment.

Existing strategies to reduce thrombosis primarily involve drug-coated surfaces or systemic anticoagulant administration. Surface coatings often release a large dose of drug immediately after implantation, creating a short-lived benefit followed by a rapid decline in protective effect. Systemic delivery, in contrast, exposes the entire body to anticoagulants, increasing bleeding risk and failing to maintain effective drug levels at the graft site over time. Inconsistent release profiles and a lack of precise temporal or spatial control can also interfere with healthy cell growth and tissue integration, ultimately compromising graft durability and patient safety.

Technology

This system delivers heparin in small diameter vascular grafts for coronary artery bypass surgeries. It features a heparin-loaded gelatin methacrylate layer between decellularized bovine pericardium and a synthetic poly(propylene fumarate) scaffold. A 3D-printed shadow mask directs UV light onto the gelatin layer for precise control of crosslinking density. By adjusting light intensity, the heparin release rate can be fine-tuned, avoiding initial high-dose spikes. This sustained release preserves endothelial cell function and boosts production of tissue factor pathway inhibitor, a natural anticoagulant that helps prevent blood clots and supports healthy vessel lining.

The defining advantage of this approach lies in its spatially and temporally resolved photochemistry paired with a biohybrid scaffold. Unlike conventional drug-eluting grafts that rely on uniform coatings or passive diffusion, the use of shadow masks enables region-specific tuning of drug release profiles. The natural tissue component enhances biocompatibility and mechanical resilience, while the synthetic layer provides structural support. Together, they maintain a balance between anticoagulation and tissue health, reducing thrombus formation and improving long-term patency compared to existing vascular graft options.

Benefits

  • Precise temporal and spatial control of heparin release
  • Sustained, slower heparin delivery minimizing high‐dose toxicity
  • Maintenance of endothelial cell function
  • Enhanced production of endogenous anticoagulant (tissue factor pathway inhibitor)
  • Reduced thrombus formation and improved graft longevity

Applications

  • Coronary bypass graft devices
  • Drug-eluting vascular prostheses
  • Thrombosis-preventing vascular implants
  • Controlled-release cardiovascular grafts
  • Biohybrid vascular graft manufacturing

Additional info

A drug-eluting small-diameter vascular graft incorporates a heparin-loaded gelatin methacrylate interlayer between decellularized bovine pericardium and poly(propylene fumarate). UV crosslinking intensity is modulated via 3D-printed shadow masks to tune gelMA crosslink density and heparin release kinetics. This approach delivers sustained, controlled anticoagulant release, preserves endothelial cell function, boosts tissue factor pathway inhibitor levels, and reduces thrombosis to enhance graft patency.

Publication

“Long-Term Sustained Drug Delivery via 3D Printed Masks for the Development of a Heparin-Loaded Interlayer in Vascular Tissue Engineering Applications” Megan Kimicata, Bhushan Mahadik, John P. Fisher ACS Applied Materials & Interfaces Vol 13/Issue 43 October 20, 2021